Knowledge base · Updated October 26, 2026 · Stefan Bensmo

Nicotine Pouch Contract Manufacturers: Factory & Supplier Guide

Short answer: nicotine pouch brands can manufacture in their own facilities or use a contract manufacturer for formulation, filling and packing. The right partner depends on verified factory capability, quality systems, regulatory responsibilities, minimum orders, capacity and ownership of the formula and data. This guide documents named manufacturers and the checks a brand should complete before signing.

A handful of factories, fifty brands

The Snus Brothers in Ödeshög, Sweden, is perhaps the clearest example. The company was founded in 2014 by brothers Kaj and Dennis, who by their own account started out in a garage. Today the facility spans 2,500 square meters with an option to expand by another 1,000, has a capacity of roughly 50 million cans per year, and its own lab for flavor and formula development. According to the company itself, around 50 brands are produced there today — some clients supply their own mix, others develop the recipe together with The Snus Brothers. Which brands they are is something the company deliberately does not disclose: it describes the confidentiality as part of its business model and does not allow outside visits to the factory.

One of the few exceptions we can document comes from our own research: FUMi, whose brand rights Altria's subsidiary Helix Sweden took over in 2025, is, according to retailer product pages, still manufactured by The Snus Brothers. It is therefore likely — though not confirmed by any official source — that several of the market's established brands in practice come from the same factory in Ödeshög.

When the big company buys the brand but not the factory

A clearer example of the same pattern is Imperial Brands' acquisition of a nicotine pouch portfolio from the Canadian contract manufacturer TJP Labs in June 2023: £65 million upfront plus a deferred payment based on sales volumes over five years, for fourteen product variants that Imperial's US subsidiary ITG Brands relaunched under its own brand in 2024. What Imperial bought was the product range — not the manufacturing company. TJP Labs, which describes itself as "North America's leading, full-service, global contract manufacturer" of bulk modern oral pouch manufacturing, continues, under the terms of the deal, to manufacture the pouches under contract for ITG Brands.

Our interpretation This is the same business logic as the FUMi case, only out in the open: buy the brand and the customer relationship, let the contract manufacturer keep the production. The likely reason is that an established contract manufacturer already has the regulatory approvals, supply chains, and production capacity in place — building or buying a factory too would have made the deal both more expensive and slower to close. The more such deals become public, the clearer it gets that owning a brand and owning its production are two separate questions in this industry.

Contract manufacturing is scaling up — and partly moving to the US

A new generation of dedicated contract manufacturers is growing alongside the established ones. Global Snus, founded roughly five years ago in Vilnius, Lithuania, runs a 3,500-square-meter facility with five automated production lines and a capacity of 3.5 million cans per month. The company is GMP-certified, sources raw materials within the EU, and was named "Best Product Manufacturer of the Year" at the InterTabac trade fair in 2025. House of Pouches in Randers, Denmark, similarly offers private-label nicotine, caffeine, and nootropic pouches with FDA registration and food-grade certifications, explicitly aimed at clients who want "their own design on our cans."

Perhaps most telling is the Swedish contract manufacturer WiJo Pouches, which in November 2025 announced a $13.5 million investment in a 55,000-square-foot facility in Lexington County, South Carolina — the company's first production facility in North America, with operations planned to start in March 2026 and around 170 new jobs. The investment lands at a time when industry trackers report 20% volume growth in oral nicotine in US convenience retail during the third quarter of 2025, with competitors such as Swisher and Reynolds American also building out their own capacity in the southeastern US. A Swedish contract manufacturer choosing to build its first overseas plant precisely in the US is a clear signal of where demand growth — and likely the regulatory and tariff exposure of not manufacturing locally — is judged to be greatest right now.

Contract manufacturing or your own factory?

The choice determines more than production cost. Contract manufacturing can shorten the path from concept to market and reduce capital needs, while in-house production provides greater control over capacity, process changes and know-how. The right model depends on market, volume, financing and how much technical and regulatory capability the business can carry itself. Our guide to the nicotine pouch manufacturing process explains the stages and controls that must be managed under either model.

Assessment For a new brand, contract manufacturing is often the realistic first step. Switching later can become expensive if the formula, process know-how, regulatory files or tooling are effectively locked to the manufacturer. The agreement should therefore anticipate a possible future transfer before the first commercial batch.

Checklist: selecting a nicotine pouch contract manufacturer

An attractive sample can tells you little about how a supplier performs during a complaint, regulatory inquiry or capacity shortage. Verify and document these points before ordering:

1. Legal entity and actual facility: who signs the agreement, where do blending, filling and packing happen, and which steps are subcontracted?
2. Markets and notifications: which markets has the facility supplied, and who owns product notification, labelling and local compliance tasks?
3. Batch release: which specifications and tests must a batch pass before shipment?
4. Traceability and recall: can materials, packaging and finished products be traced through the batch, and has the recall process been tested?
5. Ownership: who owns the formula, analytical methods, process parameters, design files and any tooling?
6. Change control: how and when is the customer told about changes to materials, suppliers, formulas, processes or facilities?
7. MOQ, capacity and lead times: what minimums apply, how are customers prioritised and what happens during demand peaks?
8. Audit rights: may the customer or an independent party inspect the facility, documentation and corrective actions?
9. Business continuity: are backup equipment, alternative materials and plans for extended downtime in place?
10. Data and complaints: who owns test results, stability data and complaint records, and how quickly must deviations be reported?

What nicotine pouch manufacturing really costs

There is no defensible universal “cost per can”. A quote reflects product specification, batch size, market documentation and which party carries development and inventory risk. A useful cost model separates:

• One-time development: formulation, pilot batches, analytical methods, stability planning, artwork and line setup.
• Direct materials: nicotine, bulking agents, flavours, pouch web, cans, labels and transport packaging.
• Conversion: labour, energy, cleaning, machine time, planned waste and yield loss.
• Quality and compliance: incoming tests, batch release, external laboratory work, documentation, notification and market-specific labelling.
• Commercial terms: minimum order quantities, deposits, storage, currency, freight, rejected batches and change requests.
• Working capital: the time between ordering materials, paying the manufacturer and receiving customer payment.

Decision rule Compare total landed and compliant cost for the same specification and volume—not two headline quotes with different testing, packaging, ownership rights or delivery terms.

Four structural challenges for independent brands

1. Capacity priority: a small customer may lose line time when a larger programme expands.
2. Compliance without scale: legal, testing and notification work is required before volumes can absorb it.
3. Distribution and working capital: inventory must often be financed before repeat demand is proven.
4. Dependency and portability: formulas, files and process knowledge can become difficult to move unless ownership and transfer support are contracted from the start.

These risks do not make independent brands uncompetitive, but they make supplier design, documentation and cash discipline as important as the flavour concept.

What it means for you

• Who actually manufactures your product is a strategic question, not just a cost question. If your brand shares a factory with twenty others, you're exposed to the same capacity shortages and supply disruptions that hit them — see our review of availability as a competitive factor.
• Notification responsibility follows whoever places the product on the market, not the manufacturer. You need to be able to document who actually produces your pouch, regardless of whose name is on the can.
• Where a contract manufacturer chooses to build new capacity is an early signal worth reading. WiJo's investment in South Carolina says something about where both demand and perceived regulatory risk are moving — it's worth tracking where your own suppliers are investing, not just what they invoice.

We help evaluate and select manufacturing partners — see product development and regulation and marketing.